26 results on '"Viviani, Laura"'
Search Results
2. European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis
- Author
-
Stern, Martin, Bertrand, Dominique Pougheon, Bignamini, Elisabetta, Corey, Mary, Dembski, Birgit, Goss, Christopher H., Pressler, Tanja, Rault, Gilles, Viviani, Laura, Elborn, J. Stuart, and Castellani, Carlo
- Published
- 2014
- Full Text
- View/download PDF
3. COVID-19 through adverse outcome pathways: building networks to better understand the disease: report of the 3rd CIAO AOP design workshop
- Author
-
Clerbaux, Laure-Alix, Amigó, Núria, Amorim, Maria João, Bal-Price, Anna, Leite, Sofia Batista, Beronius, Anna, Bezemer, Gillina F.G., Bostroem, Ann-Charlotte, Carusi, Annamaria, Coecke, Sandra, Concha, Rachel, Daskalopoulos, Evangelos P., Debernardi, Francesca, Edrosa, Eizleayne, Edwards, Steve W., Filipovska, Julija, Garcia-Reyero, Natàlia, Gavins, Felicity N.E., Halappanavar, Sabina, Hargreaves, Alan J., Hogberg, Helena, Huynh, Mylène T., Jacobson, Daniel, Josephs-Spaulding, Jonathan, Kim, Young Jun, Kong, Hyun Joon, Krebs, Catharine E., Lam, Ann, Landesmann, Brigitte, Racanelli Layton, Adrienne, Lee, Yong Oh, Macmillan, Donna S., Mantovani, Alberto, Margiotta-Casaluci, Luigi, Martens, Marvin, Masereeuw, Rosalinde, Mayasich, Sally A., Mei, Liang Merlin, Mortensen, Holly, Munoz Pineiro, Amalia, Nymark, Penny, Ohayon, Elan, Manoj Ojasi, Joshi, Paini, Alicia, Parissis, Nikolaos, Parvatam, Surat, Pistollato, Francesca, Sachana, Magdalini, Birkelund Sørli, Jorid, Sullivan, Kristie M., Sund, Jukka, Tanabe, Shihori, Tsaioun, Katya, Vinken, Mathieu, Viviani, Laura, Waspe, Jennifer, Willett, Catherine, Wittwehr, Clemens, Pharmaceutical and Pharmacological Sciences, and Experimental in vitro toxicology and dermato-cosmetology
- Abstract
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and positioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowdsourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, integrating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
- Published
- 2022
4. COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop
- Author
-
Clerbaux, Laure-Alix, Amigó, Núria, Amorim, Maria João, Bal-Price, Anna, Batista Leite, Sofia, Beronius, Anna, Bostroem, Ann-Charlotte, Carusi, Annamaria, Coecke, Sandra, Concha, Rachel, Daskalopoulos, Evangelos P, Debernardi, Francesca, Edrosa, Eizleayne, Edwards, Steve W, Filipovska, Julija, Garcia-Reyero, Natàlia, Gavins, Felicity N E, Halappanavar, Sabina, Hargreaves, Alan J, Hogberg, Helena T, Huynh, Mylène T, Jacobson, Daniel, Josephs-Spaulding, Jonathan, Kim, Young Jun, Kong, Hyun Joon, Krebs, Catharine E, Lam, Ann, Landesmann, Brigitte, Layton, Adrienne, Lee, Yong Oh, Macmillan, Donna S, Mantovani, Alberto, Margiotta-Casaluci, Luigi, Martens, Marvin, Masereeuw, Rosalinde, Mayasich, Sally A, Mei, Liang Merlin, Mortensen, Holly, Munoz Pineiro, Amalia, Nymark, Penny, Ohayon, Elan, Ojasi, Joshi, Paini, Alicia, Parissis, Nikolaos, Parvatam, Surat, Pistollato, Francesca, Sachana, Magdalini, Sørli, Jorid Birkelund, Sullivan, Kristie M, Sund, Jukka, Tanabe, Shihori, Tsaioun, Katya, Vinken, Mathieu, Viviani, Laura, Waspe, Jennifer, Willett, Catherine, Wittwehr, Clemens, Clerbaux, Laure-Alix, Amigó, Núria, Amorim, Maria João, Bal-Price, Anna, Batista Leite, Sofia, Beronius, Anna, Bostroem, Ann-Charlotte, Carusi, Annamaria, Coecke, Sandra, Concha, Rachel, Daskalopoulos, Evangelos P, Debernardi, Francesca, Edrosa, Eizleayne, Edwards, Steve W, Filipovska, Julija, Garcia-Reyero, Natàlia, Gavins, Felicity N E, Halappanavar, Sabina, Hargreaves, Alan J, Hogberg, Helena T, Huynh, Mylène T, Jacobson, Daniel, Josephs-Spaulding, Jonathan, Kim, Young Jun, Kong, Hyun Joon, Krebs, Catharine E, Lam, Ann, Landesmann, Brigitte, Layton, Adrienne, Lee, Yong Oh, Macmillan, Donna S, Mantovani, Alberto, Margiotta-Casaluci, Luigi, Martens, Marvin, Masereeuw, Rosalinde, Mayasich, Sally A, Mei, Liang Merlin, Mortensen, Holly, Munoz Pineiro, Amalia, Nymark, Penny, Ohayon, Elan, Ojasi, Joshi, Paini, Alicia, Parissis, Nikolaos, Parvatam, Surat, Pistollato, Francesca, Sachana, Magdalini, Sørli, Jorid Birkelund, Sullivan, Kristie M, Sund, Jukka, Tanabe, Shihori, Tsaioun, Katya, Vinken, Mathieu, Viviani, Laura, Waspe, Jennifer, Willett, Catherine, and Wittwehr, Clemens
- Abstract
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and positioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowdsourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, integrating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
- Published
- 2022
5. COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop
- Author
-
Afd Pharmacology, Orphan drugs development in The Netherlands: from bench to patient, Pharmacology, Clerbaux, Laure-Alix, Amigó, Núria, Amorim, Maria João, Bal-Price, Anna, Batista Leite, Sofia, Beronius, Anna, Bostroem, Ann-Charlotte, Carusi, Annamaria, Coecke, Sandra, Concha, Rachel, Daskalopoulos, Evangelos P, Debernardi, Francesca, Edrosa, Eizleayne, Edwards, Steve W, Filipovska, Julija, Garcia-Reyero, Natàlia, Gavins, Felicity N E, Halappanavar, Sabina, Hargreaves, Alan J, Hogberg, Helena T, Huynh, Mylène T, Jacobson, Daniel, Josephs-Spaulding, Jonathan, Kim, Young Jun, Kong, Hyun Joon, Krebs, Catharine E, Lam, Ann, Landesmann, Brigitte, Layton, Adrienne, Lee, Yong Oh, Macmillan, Donna S, Mantovani, Alberto, Margiotta-Casaluci, Luigi, Martens, Marvin, Masereeuw, Rosalinde, Mayasich, Sally A, Mei, Liang Merlin, Mortensen, Holly, Munoz Pineiro, Amalia, Nymark, Penny, Ohayon, Elan, Ojasi, Joshi, Paini, Alicia, Parissis, Nikolaos, Parvatam, Surat, Pistollato, Francesca, Sachana, Magdalini, Sørli, Jorid Birkelund, Sullivan, Kristie M, Sund, Jukka, Tanabe, Shihori, Tsaioun, Katya, Vinken, Mathieu, Viviani, Laura, Waspe, Jennifer, Willett, Catherine, Wittwehr, Clemens, Afd Pharmacology, Orphan drugs development in The Netherlands: from bench to patient, Pharmacology, Clerbaux, Laure-Alix, Amigó, Núria, Amorim, Maria João, Bal-Price, Anna, Batista Leite, Sofia, Beronius, Anna, Bostroem, Ann-Charlotte, Carusi, Annamaria, Coecke, Sandra, Concha, Rachel, Daskalopoulos, Evangelos P, Debernardi, Francesca, Edrosa, Eizleayne, Edwards, Steve W, Filipovska, Julija, Garcia-Reyero, Natàlia, Gavins, Felicity N E, Halappanavar, Sabina, Hargreaves, Alan J, Hogberg, Helena T, Huynh, Mylène T, Jacobson, Daniel, Josephs-Spaulding, Jonathan, Kim, Young Jun, Kong, Hyun Joon, Krebs, Catharine E, Lam, Ann, Landesmann, Brigitte, Layton, Adrienne, Lee, Yong Oh, Macmillan, Donna S, Mantovani, Alberto, Margiotta-Casaluci, Luigi, Martens, Marvin, Masereeuw, Rosalinde, Mayasich, Sally A, Mei, Liang Merlin, Mortensen, Holly, Munoz Pineiro, Amalia, Nymark, Penny, Ohayon, Elan, Ojasi, Joshi, Paini, Alicia, Parissis, Nikolaos, Parvatam, Surat, Pistollato, Francesca, Sachana, Magdalini, Sørli, Jorid Birkelund, Sullivan, Kristie M, Sund, Jukka, Tanabe, Shihori, Tsaioun, Katya, Vinken, Mathieu, Viviani, Laura, Waspe, Jennifer, Willett, Catherine, and Wittwehr, Clemens
- Published
- 2022
6. Impact of the A (H1N1) pandemic influenza (season 2009–2010) on patients with cystic fibrosis
- Author
-
Viviani, Laura, Assael, Baroukh M., and Kerem, Eitan
- Published
- 2011
- Full Text
- View/download PDF
7. Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age
- Author
-
Viviani, Laura, Bossi, Anna, and Assael, Baroukh Maurice
- Published
- 2011
- Full Text
- View/download PDF
8. Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework
- Author
-
Nymark, Penny, primary, Sachana, Magdalini, additional, Leite, Sofia Batista, additional, Sund, Jukka, additional, Krebs, Catharine E., additional, Sullivan, Kristie, additional, Edwards, Stephen, additional, Viviani, Laura, additional, Willett, Catherine, additional, Landesmann, Brigitte, additional, and Wittwehr, Clemens, additional
- Published
- 2021
- Full Text
- View/download PDF
9. An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter.
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Davies, Gwyneth, Stanojevic, Sanja, Raywood, Emma, Duncan, Julie A, Stocks, Janet, Lum, Sooky, Bush, Andrew, Viviani, Laura, Wade, Angie, Calder, Alistair, Owens, Catherine M, Goubau, Christophe, Carr, Siobhán B, Bossley, Cara J, Pao, Caroline, Aurora, Paul, London Cystic Fibrosis Collaboration, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Davies, Gwyneth, Stanojevic, Sanja, Raywood, Emma, Duncan, Julie A, Stocks, Janet, Lum, Sooky, Bush, Andrew, Viviani, Laura, Wade, Angie, Calder, Alistair, Owens, Catherine M, Goubau, Christophe, Carr, Siobhán B, Bossley, Cara J, Pao, Caroline, Aurora, Paul, and London Cystic Fibrosis Collaboration
- Abstract
Lung clearance index (LCI) in the early years was associated with LCI during adolescence in children with cystic fibrosis. Pre-school LCI may help to identify children in whom treatment could be intensified.
- Published
- 2020
10. An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
- Author
-
Davies, Gwyneth, primary, Stanojevic, Sanja, additional, Raywood, Emma, additional, Duncan, Julie A., additional, Stocks, Janet, additional, Lum, Sooky, additional, Bush, Andrew, additional, Viviani, Laura, additional, Wade, Angie, additional, Calder, Alistair, additional, Owens, Catherine M., additional, Goubau, Christophe, additional, Carr, Siobhán B., additional, Bossley, Cara J., additional, Pao, Caroline, additional, and Aurora, Paul, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis
- Author
-
Boëlle Pierre-Yves, Viviani Laura, Busson Pierre-Francois, Olesen Hanne V, Ravilly Sophie, Stern Martin, Assael Baroukh M, Barreto Celeste, Drevinek Pavel, Thomas Muriel, Krivec Uros, Mei-Zahav Meir, Vibert Jean-François, Clement Annick, Mehta Anil, and Corvol Harriet
- Subjects
Cystic fibrosis ,Forced expiratory volume in one second ,Body mass index ,Registry ,Medicine - Abstract
Abstract Background The clinical course of Cystic Fibrosis (CF) is usually measured using the percent predicted FEV1 and BMI Z-score referenced against a healthy population, since achieving normality is the ultimate goal of CF care. Referencing against age and sex matched CF peers may provide valuable information for patients and for comparison between CF centers or populations. Here, we used a large database of European CF patients to compute CF specific reference equations for FEV1 and BMI, derived CF-specific percentile charts and compared these European data to their nearest international equivalents. Methods 34859 FEV1 and 40947 BMI observations were used to compute European CF specific percentiles. Quantile regression was applied to raw measurements as a function of sex, age and height. Results were compared with the North American equivalent for FEV1 and with the WHO 2007 normative values for BMI. Results FEV1 and BMI percentiles illustrated the large variability between CF patients receiving the best current care. The European CF specific percentiles for FEV1 were significantly different from those in the USA from an earlier era, with higher lung function in Europe. The CF specific percentiles for BMI declined relative to the WHO standard in older children. Lung function and BMI were similar in the two largest contributing European Countries (France and Germany). Conclusion The CF specific percentile approach applied to FEV1 and BMI allows referencing patients with respect to their peers. These data allow peer to peer and population comparisons in CF patients.
- Published
- 2012
- Full Text
- View/download PDF
12. Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop
- Author
-
Bruysters, Martijn W.P., Schiffelers, Marie Jeanne, Hoonakker, Marieke, Jungbaeck, Carmen, Ragan, Ian, Rommel, Eddy, van der Stappen, Ton, Viviani, Laura, Hessel, Ellen V., Akkermans, Arnoud M., Vandebriel, Rob J., UU LEG Research USG Public Matters, Public Management, Sub 3V Centrum ULS, UU LEG Research USG Public Matters, Public Management, and Sub 3V Centrum ULS
- Subjects
0301 basic medicine ,Quality Control ,Process management ,Drug Industry ,Consistency approach ,Drivers ,Computer science ,media_common.quotation_subject ,Bioengineering ,Constructive ,3R ,Applied Microbiology and Biotechnology ,03 medical and health sciences ,Regulatory acceptance ,0302 clinical medicine ,Consistency (negotiation) ,Immunology and Microbiology(all) ,Taverne ,Humans ,Quality (business) ,030212 general & internal medicine ,media_common ,Pharmacology ,Government ,Vaccines ,General Immunology and Microbiology ,General Medicine ,Congresses as Topic ,Vaccine batch release ,030104 developmental biology ,Quality management system ,Barriers ,Biotechnology - Abstract
Safety and potency assessment for batch release testing of established vaccines still relies partly on animal tests. An important avenue to move to batch release without animal testing is the consistency approach. This approach is based on thorough characterization of the vaccine, and the principle that the quality of subsequent batches is the consequence of the application of consistent production of batches monitored by a GMP quality system. Efforts to implement the consistency approach are supported by several drivers from industry, government, and research, but there are also several barriers that must be overcome. A workshop entitled "Consistency Approach, Drivers and Barriers" was organized, which aimed to discuss and identify drivers and barriers for the implementation of the 3Rs in the consistency approach from three different perspectives/domains (industry, regulatory and science frameworks). The workshop contributed to a better understanding of these drivers and barriers and resulted in recommendations to improve the overall regulatory processes for the consistency approach. With this report, we summarise the outcome of this workshop and intend to offer a constructive contribution to the international discussion on regulatory acceptance of the consistency approach.
- Published
- 2017
13. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF)
- Author
-
Viviani, Laura, Harrison, Michael J., Zolin, Anna, Haworth, Charles S., and Floto, R. Andres
- Published
- 2016
- Full Text
- View/download PDF
14. Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop
- Author
-
UU LEG Research USG Public Matters, Public Management, Sub 3V Centrum ULS, Bruysters, Martijn W.P., Schiffelers, Marie Jeanne, Hoonakker, Marieke, Jungbaeck, Carmen, Ragan, Ian, Rommel, Eddy, van der Stappen, Ton, Viviani, Laura, Hessel, Ellen V., Akkermans, Arnoud M., Vandebriel, Rob J., UU LEG Research USG Public Matters, Public Management, Sub 3V Centrum ULS, Bruysters, Martijn W.P., Schiffelers, Marie Jeanne, Hoonakker, Marieke, Jungbaeck, Carmen, Ragan, Ian, Rommel, Eddy, van der Stappen, Ton, Viviani, Laura, Hessel, Ellen V., Akkermans, Arnoud M., and Vandebriel, Rob J.
- Published
- 2017
15. The second study of infectious intestinal disease (IID2): increased rates of recurrent diarrhoea in individuals aged 65 years and above
- Author
-
Tam, Clarence C, Viviani, Laura, Rodrigues, Laura C, and O'Brien, Sarah J
- Abstract
BACKGROUND: Infectious intestinal disease (IID) is a major health and economic burden in high-income countries. In the UK, there are an estimated 17 million IID cases annually, of which 6 million are caused by the 12 most common pathogens. Host factors that influence risk of IID are not well understood. METHODS: We analyzed data from the IID2 Study, a UK cohort that measured IID incidence, to investigate factors associated with recurrent IID. We calculated rates of IID by age group, sex, previous episodes experienced, and socioecomic indicators. We used Cox models to investigate factors associated with recurrent illness. RESULTS: The rate of IID was five times higher among infants than those aged 65 years and above (hazard ratio, HR = 5.0, 95% CI: 3.1 - 8.0). However, the association between previous IID and a subsequent IID episode was stronger in the elderly. Among those aged 65 years and above, each additional IID episode increased the rate of subsequent IID three-fold (HR = 3.1, 95% CI: 2.5 - 3.7). Among infants, the corresponding increase was 1.7-fold (HR = 1.7, 95% CI: 1.3 - 2.3). CONCLUSIONS: Elderly populations have a high propensity for recurrent IID. More detailed studies are needed to identify vulnerable subgroups and susceptibility factors, and inform adequate control policies among the elderly.
- Published
- 2013
16. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice
- Author
-
Tam, Clarence C, Rodrigues, Laura C, Viviani, Laura, Dodds, Julie P, Evans, Meirion R, Hunter, Paul R, Gray, Jim J, Letley, Louise H, Rait, Greta, Tompkins, David S, O'Brien, Sarah J, and IID2 Study Executive Committee
- Abstract
OBJECTIVES: To estimate, overall and by organism, the incidence of infectious intestinal disease (IID) in the community, presenting to general practice (GP) and reported to national surveillance. DESIGN: Prospective, community cohort study and prospective study of GP presentation conducted between April 2008 and August 2009. SETTING: Eighty-eight GPs across the UK recruited from the Medical Research Council General Practice Research Framework and the Primary Care Research Networks. PARTICIPANTS: 6836 participants registered with the 88 participating practices in the community study; 991 patients with UK-acquired IID presenting to one of 37 practices taking part in the GP presentation study. MAIN OUTCOME MEASURES: IID rates in the community, presenting to GP and reported to national surveillance, overall and by organism; annual IID cases and GP consultations by organism. RESULTS: The overall rate of IID in the community was 274 cases per 1000 person-years (95% CI 254 to 296); the rate of GP consultations was 17.7 per 1000 person-years (95% CI 14.4 to 21.8). There were 147 community cases and 10 GP consultations for every case reported to national surveillance. Norovirus was the most common organism, with incidence rates of 47 community cases per 1000 person-years and 2.1 GP consultations per 1000 person-years. Campylobacter was the most common bacterial pathogen, with a rate of 9.3 cases per 1000 person-years in the community, and 1.3 GP consultations per 1000 person-years. We estimate that there are up to 17 million sporadic, community cases of IID and 1 million GP consultations annually in the UK. Of these, norovirus accounts for 3 million cases and 130,000 GP consultations, and Campylobacter is responsible for 500,000 cases and 80,000 GP consultations. CONCLUSIONS: IID poses a substantial community and healthcare burden in the UK. Control efforts must focus particularly on reducing the burden due to Campylobacter and enteric viruses.
- Published
- 2011
17. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis
- Author
-
Elborn, J. Stuart, primary, Bell, Scott C., additional, Madge, Susan L., additional, Burgel, Pierre-Regis, additional, Castellani, Carlo, additional, Conway, Steven, additional, De Rijcke, Karleen, additional, Dembski, Birgit, additional, Drevinek, Pavel, additional, Heijerman, Harry G.M., additional, Innes, J. Alistair, additional, Lindblad, Anders, additional, Marshall, Bruce, additional, Olesen, Hanne V., additional, Reimann, Andreas L., additional, Solé, Ampara, additional, Viviani, Laura, additional, Wagner, Thomas O.F., additional, Welte, Tobias, additional, and Blasi, Francesco, additional
- Published
- 2015
- Full Text
- View/download PDF
18. Future trends in cystic fibrosis demography in 34 European countries
- Author
-
Burgel, Pierre-Régis, primary, Bellis, Gil, additional, Olesen, Hanne V., additional, Viviani, Laura, additional, Zolin, Anna, additional, Blasi, Francesco, additional, and Elborn, J. Stuart, additional
- Published
- 2015
- Full Text
- View/download PDF
19. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
- Author
-
Viviani, Laura, primary, Zolin, Anna, additional, Mehta, Anil, additional, and Olesen, Hanne Vebert, additional
- Published
- 2014
- Full Text
- View/download PDF
20. Estimating the Incidence of Acute Infectious Intestinal Disease in the Community in the UK: A Retrospective Telephone Survey.
- Author
-
Viviani, Laura, van der Es, Mike, Irvine, Lisa, Tam, Clarence C., Rodrigues, Laura C., Jackson, Kathryn A., O’Brien, Sarah J., Hunter, Paul R., and null, null
- Subjects
- *
DISEASE incidence , *INTESTINAL diseases , *COMMUNICABLE diseases , *BURDEN of care , *TELEPHONE surveys - Abstract
Objectives: To estimate the burden of intestinal infectious disease (IID) in the UK and determine whether disease burden estimations using a retrospective study design differ from those using a prospective study design. Design/Setting: A retrospective telephone survey undertaken in each of the four countries comprising the United Kingdom. Participants were randomly asked about illness either in the past 7 or 28 days. Participants: 14,813 individuals for all of whom we had a legible recording of their agreement to participate Outcomes: Self-reported IID, defined as loose stools or clinically significant vomiting lasting less than two weeks, in the absence of a known non-infectious cause. Results: The rate of self-reported IID varied substantially depending on whether asked for illness in the previous 7 or 28 days. After standardising for age and sex, and adjusting for the number of interviews completed each month and the relative size of each UK country, the estimated rate of IID in the 7-day recall group was 1,530 cases per 1,000 person-years (95% CI: 1135–2113), while in the 28-day recall group it was 533 cases per 1,000 person-years (95% CI: 377–778). There was no significant variation in rates between the four countries. Rates in this study were also higher than in a related prospective study undertaken at the same time. Conclusions: The estimated burden of disease from IID varied dramatically depending on study design. Retrospective studies of IID give higher estimates of disease burden than prospective studies. Of retrospective studies longer recall periods give lower estimated rates than studies with short recall periods. Caution needs to be exercised when comparing studies of self-reported IID as small changes in study design or case definition can markedly affect estimated rates. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Defective CFTR Expression and Function Are Detectable in Blood Monocytes: Development of a New Blood Test for Cystic Fibrosis
- Author
-
Sorio, Claudio, primary, Buffelli, Mario, additional, Angiari, Chiara, additional, Ettorre, Michele, additional, Johansson, Jan, additional, Vezzalini, Marzia, additional, Viviani, Laura, additional, Ricciardi, Mario, additional, Verzè, Genny, additional, Assael, Baroukh Maurice, additional, and Melotti, Paola, additional
- Published
- 2011
- Full Text
- View/download PDF
22. Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis.
- Author
-
Bo‰lle, Pierre-Yves, Viviani, Laura, Busson, Pierre-Francois, Olesen, Hanne V., Ravilly, Sophie, Stern, Martin, Assael, Baroukh M., Barreto, Celeste, Drevinek, Pavel, Thomas, Muriel, Krivec, Uros, Mei-Zahav, Meir, Vibert, Jean-Fran‡ois, Clement, Annick, Mehta, Anil, and Corvol, Harriet
- Subjects
- *
CYSTIC fibrosis , *GENETIC disorders , *MEDICAL genetics , *PANCREATIC diseases , *PATIENTS - Abstract
Background: The clinical course of Cystic Fibrosis (CF) is usually measured using the percent predicted FEV1 and BMI Z-score referenced against a healthy population, since achieving normality is the ultimate goal of CF care. Referencing against age and sex matched CF peers may provide valuable information for patients and for comparison between CF centers or populations. Here, we used a large database of European CF patients to compute CF specific reference equations for FEV1 and BMI, derived CF-specific percentile charts and compared these European data to their nearest international equivalents. Methods: 34859 FEV1 and 40947 BMI observations were used to compute European CF specific percentiles. Quantile regression was applied to raw measurements as a function of sex, age and height. Results were compared with the North American equivalent for FEV1 and with the WHO 2007 normative values for BMI. Results: FEV1 and BMI percentiles illustrated the large variability between CF patients receiving the best current care. The European CF specific percentiles for FEV1 were significantly different from those in the USA from an earlier era, with higher lung function in Europe. The CF specific percentiles for BMI declined relative to the WHO standard in older children. Lung function and BMI were similar in the two largest contributing European Countries (France and Germany). Conclusion: The CF specific percentile approach applied to FEV1 and BMI allows referencing patients with respect to their peers. These data allow peer to peer and population comparisons in CF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.
- Author
-
Clerbaux LA, Amigó N, Amorim MJ, Bal-Price A, Batista Leite S, Beronius A, Bezemer GFG, Bostroem AC, Carusi A, Coecke S, Concha R, Daskalopoulos EP, De Bernardi F, Edrosa E, Edwards SW, Filipovska J, Garcia-Reyero N, Gavins FNE, Halappanavar S, Hargreaves AJ, Hogberg HT, Huynh MT, Jacobson D, Josephs-Spaulding J, Kim YJ, Kong HJ, Krebs CE, Lam A, Landesmann B, Layton A, Lee YO, Macmillan DS, Mantovani A, Margiotta-Casaluci L, Martens M, Masereeuw R, Mayasich SA, Mei LM, Mortensen H, Munoz Pineiro A, Nymark P, Ohayon E, Ojasi J, Paini A, Parissis N, Parvatam S, Pistollato F, Sachana M, Sørli JB, Sullivan KM, Sund J, Tanabe S, Tsaioun K, Vinken M, Viviani L, Waspe J, Willett C, and Wittwehr C
- Subjects
- Humans, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Adverse Outcome Pathways, COVID-19 complications
- Abstract
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and positioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowdsourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, integrating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
- Published
- 2022
- Full Text
- View/download PDF
24. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.
- Author
-
Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, and Blasi F
- Subjects
- Adult, Advisory Committees, Cystic Fibrosis psychology, Disease Management, Europe, Health Planning, Humans, Lung Transplantation, Patient Compliance, Pulmonary Medicine organization & administration, Social Support, Societies, Medical, Transition to Adult Care organization & administration, Workforce, Cystic Fibrosis therapy, Health Services Needs and Demand, Pulmonary Medicine education, Terminal Care
- Abstract
The improved survival in people with cystic fibrosis has led to an increasing number of patients reaching adulthood. This trend is likely to be maintained over the next decades, suggesting a need to increase the number of centres with expertise in the management of adult patients with cystic fibrosis. These centres should be capable of delivering multidisciplinary care addressing the complexity of the disease, in addition to addressing the psychological burden on patients and their families. Further issues that require attention are organ transplantation and end of life management.Lung disease in adults with cystic fibrosis drives most of the clinical care requirements, and major life-threatening complications, such as respiratory infection, respiratory failure, pneumothorax and haemoptysis, and the management of lung transplantation require expertise from trained respiratory physicians. The taskforce therefore strongly reccommends that medical leadership in multidisciplinary adult teams should be attributed to a respiratory physician adequately trained in cystic fibrosis management.The task force suggests the implementation of a core curriculum for trainees in adult respiratory medicine and the selection and accreditation of training centres that deliver postgraduate training to the standards of the HERMES programme., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
25. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.
- Author
-
Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, and Olesen H
- Subjects
- Adolescent, Adult, Aged, Body Mass Index, Child, Cystic Fibrosis complications, Disease Progression, Female, Forced Expiratory Volume, Humans, Linear Models, Logistic Models, Male, Middle Aged, Odds Ratio, Respiratory Insufficiency etiology, Risk Factors, Severity of Illness Index, Young Adult, Cystic Fibrosis physiopathology, Diabetes Mellitus etiology, Exocrine Pancreatic Insufficiency etiology, Pseudomonas Infections complications, Pseudomonas aeruginosa, Registries, Respiratory Insufficiency physiopathology
- Abstract
Pulmonary insufficiency is the main cause of death in cystic fibrosis (CF). We analysed forced expiratory volume in 1 s (FEV1) data of 14,732 patients registered in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database in 2007. We used linear and logistic regressions to investigate associations between FEV1 % predicted and clinical outcomes. Body mass index (BMI), chronic infection by Pseudomonas aeruginosa, pancreatic status and CF-related diabetes (CFRD) showed a statistically significant (all p<0.0001) and clinically relevant effect on FEV1 % pred after adjusting for age. Patients with a lower BMI experience a six-fold increased odds ratio (95% CI 5.0-7.3) of having severe lung disease (FEV1 <40% pred) compared to patients with normal BMI. Being chronically infected with P. aeruginosa increases the odds ratio of severe lung disease by 2.4 (95% CI 2.0-2.7), and patients with pancreatic insufficiency experience a 2.0-fold increased odds ratio (95% CI 1.6-2.5) of severe lung disease compared to pancreatic sufficient patients. Patients with CFRD have a 1.8-fold increased odds ratio (95% CI 1.6-2.2) compared to patients not affected. These potential risk factors for pulmonary disease in patients with CF are to some degree preventable or treatable. We emphasise the importance of their early identification through frequent routine tests, the implementation of infection control measures, and a timely initiation of relevant therapies.
- Published
- 2014
- Full Text
- View/download PDF
26. The second study of infectious intestinal disease (IID2): increased rates of recurrent diarrhoea in individuals aged 65 years and above.
- Author
-
Tam CC, Viviani L, Rodrigues LC, and O'Brien SJ
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Child, Child, Preschool, Cohort Studies, Female, Humans, Incidence, Infant, Male, Middle Aged, Recurrence, Risk Factors, United Kingdom epidemiology, Young Adult, Communicable Diseases epidemiology, Diarrhea epidemiology, Intestinal Diseases epidemiology
- Abstract
Background: Infectious intestinal disease (IID) is a major health and economic burden in high-income countries. In the UK, there are an estimated 17 million IID cases annually, of which 6 million are caused by the 12 most common pathogens. Host factors that influence risk of IID are not well understood., Methods: We analyzed data from the IID2 Study, a UK cohort that measured IID incidence, to investigate factors associated with recurrent IID. We calculated rates of IID by age group, sex, previous episodes experienced, and socioecomic indicators. We used Cox models to investigate factors associated with recurrent illness., Results: The rate of IID was five times higher among infants than those aged 65 years and above (hazard ratio, HR = 5.0, 95% CI: 3.1 - 8.0). However, the association between previous IID and a subsequent IID episode was stronger in the elderly. Among those aged 65 years and above, each additional IID episode increased the rate of subsequent IID three-fold (HR = 3.1, 95% CI: 2.5 - 3.7). Among infants, the corresponding increase was 1.7-fold (HR = 1.7, 95% CI: 1.3 - 2.3)., Conclusions: Elderly populations have a high propensity for recurrent IID. More detailed studies are needed to identify vulnerable subgroups and susceptibility factors, and inform adequate control policies among the elderly.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.